Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

NCT ID: NCT03299660

Last Updated: 2023-03-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-30
• Study Completion Date: 2023-02-28

Brief Summary

This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer. It is hypothesised that this may enhance the pathological and imaging response rates whilst potentially reducing the relapse rates. Participants will receive standard long course chemoradiotherapy (LCCRT) treatment with radiotherapy and 5-fluorouracil (5 FU)/Capecitabine for 6 weeks, this then followed by 4 cycles of Avelumab and then surgical resection. The trial will measure disease response just prior to surgery and participants will be followed up for a minimum of 18 months (from study entry) and up to 42 months.

Conditions

Rectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Avelumab

Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection

Group Type: EXPERIMENTAL

Avelumab

Intervention Type: DRUG

Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT

5 Fluorouracil

Intervention Type: DRUG

5FU continuous infusion 225mg/m2/day during radiotherapy

Capecitabine Pill

Intervention Type: DRUG

Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy

Radiotherapy

Intervention Type: RADIATION

50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week

Surgical Resection

Intervention Type: PROCEDURE

Surgical resection of tumour mass post radiotherapy and chemotherapy

Interventions

Avelumab

Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT

Intervention Type: DRUG

5 Fluorouracil

5FU continuous infusion 225mg/m2/day during radiotherapy

Intervention Type: DRUG

Capecitabine Pill

Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy

Intervention Type: DRUG

Radiotherapy

50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week

Intervention Type: RADIATION

Surgical Resection

Surgical resection of tumour mass post radiotherapy and chemotherapy

Intervention Type: PROCEDURE

Other Intervention Names

MSB0010718C

Eligibility Criteria

Inclusion Criteria

1. Male or female aged ≥ 18 years at screening

2. Patients with histologically confirmed rectal adenocarcinoma clinical stage T3bN1-N2M0, T3c/dN0-N2M0, T4N0-N2M0 (see Appendix 1),1 as defined by pelvic MRI

3. Planned to receive neoadjuvant long course chemoradiotherapy (50.4 Gy, with infusional 5FU or capecitabine) followed by curative total mesorectal excision plus abdomino-perineal resection or anterior resection

4. Lower border of tumour must be within 12 cm from anal verge

5. Measurable disease by RECIST1.12

6. ECOG Performance Status 0-1

7. Patients must be willing to provide fresh (where possible) and archival tumour tissue samples for translational studies at specified time points

8. Adequate organ function

1. Absolute neutrophil count ≥1.5 x 109/L

2. Platelet count ≥100 x 109/L

3. Haemoglobin ≥ 90 g/L (may have been transfused)

4. Creatinine ≤ 1.5 x upper normal limit OR measured creatinine clearance ≥ 50 mL/minute

5. Total bilirubin ≤ 1.5 x upper normal limit

6. AST/ALT ≤ 2.5 x upper normal limit

9. Female patients of childbearing potential must have a negative urine or serum pregnancy test at screening

10. Both male and female patients should be willing to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) if the risk of conception exists

11. Has provided written informed consent for the trial

12. Agrees to comply with trial therapy or trial-related investigations and evaluations

Exclusion Criteria

1. Patients with disease outside the pelvis

2. Prior pelvic radiotherapy

3. Participation in another interventional clinical trial within 30 days of registration (participation in observational studies are permitted)

4. Concurrent anti-cancer treatment

5. Concurrent treatment with a non-permitted drug (Section 8.3.2)

6. Major surgery for any reason within 4 weeks of registration (except defunctioning stoma creation with the patient having fully recovered from this procedure)

7. Current use of immunosuppressive medication. Except for the following: (a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); (b). Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; (c). Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication); (d) Short-term administration of systemic steroids (that is, for allergic reactions or the management of irAEs) is allowed while on study.

Note: Patients receiving bisphosphonate or denosumab are eligible

8. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible

9. Active or history of immunodeficiencies

10. Has received prior therapy with an anti-PD1, anti-PDL1, anti-PDL2 or anti-CTLA-4 agents

11. Has clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to registration), myocardial infarction (< 6 months prior to registration), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious cardiac arrhythmia requiring medication.

12. Has an active infection requiring systemic therapy

13. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study

14. Prior malignancies within 3 years of registration (with the exception of non- melanomatous skin cancer)

15. Prior organ transplantation, including allogeneic stem-cell transplantation

16. A known history of testing positive for HIV or known acquired immunodeficiency syndrome (AIDS)

17. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test is positive)

18. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (CTCAE v4.03 grade ≥ 3)

19. Is pregnant or lactating

20. Vaccination within 4 weeks of registration and while on trials is prohibited except for administration of inactivated vaccines

21. Known deficiency of dihydropyrimidine dehydrogenase

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peter MacCallum Cancer Centre, Australia

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Michael, A/Prof

Role: PRINCIPAL_INVESTIGATOR

Peter MacCallum Cancer Centre, Australia

Locations

Prince of Wales Hospital

Randwick, New South Wales, Australia

Royal North Shore

St Leonards, New South Wales, Australia

Box Hill Hospital

Box Hill, Victoria, Australia

Cabrini Hospital

Malvern, Victoria, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Monash Health

Melbourne, Victoria, Australia

Alfred Hospital

Prahran, Victoria, Australia

Countries

Australia

Other Identifiers

AveRec

Identifier Type: -

Identifier Source: org_study_id